Current Report Filing (8-k)
June 20 2017 - 6:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported) June 19,
2017
INNOVUS PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
000-52991
|
90-0814124
|
(State
or other jurisdiction of incorporation)
|
(Commission
File
Number)
|
(IRS
Employer Identification No.)
|
9171
Towne Centre Drive, Suite 440,
San Diego, CA
|
|
92122
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(858) 964-5123
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
In this
report, “Innovus Pharmaceuticals,” “Innovus
Pharma,” “the Company”, “we,”
“us” and “our” refer to Innovus
Pharmaceuticals, Inc., and/or one or more of our wholly-owned
subsidiaries, unless the context otherwise provides. Innovus
Pharma® is a registered service mark of Innovus
Pharmaceuticals, Inc.
Section 5 – Corporate Governance and Management
Item 5.07 – Submission of Matters to a Vote of Security
Holders
The
Company held its Annual Meeting on June 19, 2017. A total of
120,191,807 shares of Common Stock, representing 79.84% of the
shares outstanding and eligible to vote and constituting a quorum,
were represented in person or by valid proxies at the Annual
Meeting. The final results for each of the matters submitted to a
vote of shareholders at the Annual Meeting are as
follows:
Proposal 1
: All
of the nominees
for the Board of Directors were elected and will hold office until
a successor is elected and qualified, or until the Director
resigns, is removed or becomes disqualified, by the votes set forth
below:
Nominee
|
For
|
Withheld
|
Broker Non-Votes
|
Dr. Bassam Damaj, Ph.D
|
59,933,711
|
987,707
|
59,270,389
|
Dr. Henry Esber, Ph.D
|
60,108,816
|
812,602
|
59,270,389
|
Vivian Liu
|
60,095,516
|
825,902
|
59,270,389
|
Dr. Ziad Mirza, M.D.
|
60,108,011
|
813,407
|
59,270,389
|
Proposal 2
: The appointment of Hall & Company, Inc. as
the Company’s independent registered public accounting firm
for the fiscal year ending December 31, 2017 was ratified by the
Company’s shareholders by the votes set forth in the table
below:
For
|
Against
|
Abstain
|
115,063,862
|
4,749,162
|
378,783
|
Section 8 – Other Events
Item 8.01 Other Events
On June 20, 2017, the Company announced that
in order to
expand its sales and marketing team in preparation of its launch of
FlutiCare
TM
in the 4th Quarter
of 2017,
Robert C. Verfurth has been
appointed the Vice President of Sales and Marketing. Verfurth came
back to Innovus Pharma after spending the previous two years
building a commercial team and launching a new blood-based colon
cancer technology at Applied Proteomics, Inc. He was also part of
the Innovus Pharma team back in 2013 in a similar role. Mr.
Verfurth was also part of the marketing and sales team at Apricus
Biosciences (NASDAQ: APRI), a specialty pharmaceutical company.
Prior to Apricus, Mr. Verfurth was Vice President, US Sales-West
for Becton Dickinson Diagnostics. Before that, he served as Vice
President, US Sales and Support for the molecular diagnostic
start-up GeneOhm Sciences beginning in 2005. GeneOhm Sciences was
purchased by Becton Dickinson, after which Mr. Verfurth continued
his sales leadership responsibilities in the molecular and
infectious disease product areas. Prior to GeneOhm, Mr. Verfurth
held a number of commercial roles, including Vice President of
Sales at both Prometheus Laboratories and Dianon Systems. He also
spent six years in the United States Air force, achieving the rank
of Captain. Mr. Verfurth earned a Bachelor of Science degree in
Business Administration from the University of Notre Dame and a
Master's of Science degree in Systems Management from the
University of Southern California
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
INNOVUS
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
Date:
June 20, 2017
|
By:
|
/S/
Bassam Damaj
|
|
|
|
Bassam
Damaj, CEO
|